Damora Therapeutics, Inc. — Company profile
Denmark
Last price 21.67 USD (Oct 30, 2026, 2:14 PM EDT) · Market cap 1.34B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Details
| Name | Damora Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 7 |
| Founded | 2011 |
| Ipo Date | 2020-10-29 |
| Ceo | Jennifer Jarrett |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | KYG2646Y1044 |
| Cusip | G2646Y104 |
| Cik | 1800315 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Jennifer A. Jarrett M.B.A. | Chief Executive Officer, President and Director |
| Garrett Winslow Esq. | Senior Vice President, General Counsel and Corporate Secretary |
| Ulf J. Nilsson Ph.D. | Co-Founder |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |
| Brian Burkavage CPA | Senior Vice President of Finance, Principal Financial and Accounting Officer |
| Sherwin Sattarzadeh | Chief Operating Officer |
| Dr. Becker Hewes M.D. | Chief Medical Officer |
Contact
| Address | Building 23, Suite 105, Waltham, Massachusetts 02453, United States |
| Phone | 781 281 9020 |
| Website | https://www.damoratx.com |